Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 157

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 157
---
 net sales growth of 7.8 percent and the positive impact of 130 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2025, this increase included operational net sales growth of 6.9 percent and a neutral impact of less than one basis point from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth during the second quarter of 2025 included organic net sales growth of 7.8 percent. Operational net sales growth during the first six months of 2025 included organic net sales growth of 6.7 percent and the positive impact of 20 basis points from our acquisition of the endoluminal vacuum therapy portfolio of Braun during the first quarter of 2024. Organic net sales growth in both periods was primarily driven by our biliary franchise led by our AXIOS™ Stent and Delivery System, and our endoluminal surgery franchise.

43

Urology

Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $676 million during the second quarter and $1.310 billion during the first six months of 2025 represented 13 percent of our consolidated net sales in both periods. Urology net sales increased $152 million, or 28.9 percent, during the second quarter and $272 million, or 26.2 percent, during the first six months of 2025, compared to the prior year periods. During the second quarter of 2025, this increase included operational net sales growth of 28.0 percent and the positive impact of 80 basis points from foreign currency fluctuations, compared to the prior year period. During the first six months of 2025, this increase included operational net sales growth of 26.3 percent and a negative impact of 10 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth included organic net sales growth of 6.3 percent during the second quarter of 2025 and 5.4 percent during the first six months of 2025, and the positive impact of 2,170 and 2,090 basis points, respectively, from our acquisition of Axonics during the fourth quarter of 2024. Organic net sales growth in both periods was primarily driven by our stone